Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WLF Files Citizen Petition With FDA To Clarify Off-Label Dissemination

This article was originally published in The Gray Sheet

Executive Summary

FDA violated the terms of a Washington Legal Foundation v. Henney federal appeals court decision when it cited New Star Lasers for dissemination of peer-reviewed articles to doctors, WLF argues in a May 23 citizen petition to the agency.

You may also be interested in...



Disclaimers Do Not Remedy Content Violations – FDA Warning Letter

Providing disclaimers for material that promotes an uncleared or unapproved use does not remedy content violations, FDA's device center Promotion and Policy Staff emphasize in a Nov. 5 letter to Diomed

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel